Neurobo Pharmaceuticals Stock Today

NRBO Stock  USD 4.22  0.13  3.18%   

Performance

9 of 100

 
Weak
 
Strong
OK

Odds Of Distress

Less than 8

 
High
 
Low
Low
Neurobo Pharmaceuticals is selling at 4.22 as of the 25th of July 2024; that is 3.18 percent increase since the beginning of the trading day. The stock's open price was 4.09. Neurobo Pharmaceuticals has only a 8 % chance of going through financial distress over the next few years but had a somewhat ok performance during the last 90 days. Equity ratings for Neurobo Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 25th of June 2024 and ending today, the 25th of July 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
5th of August 2016
Category
Healthcare
Classification
Health Care
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts. The company has 8.22 M outstanding shares of which 92.6 K shares are now shorted by private and institutional investors with about 1.2 trading days to cover. More on Neurobo Pharmaceuticals

Moving against Neurobo Stock

  0.75CANB Can B CorpPairCorr
  0.74DIS Walt Disney Financial Report 14th of August 2024 PairCorr
  0.73PME Pingtan Marine EnterprisePairCorr
  0.55MCD McDonalds Sell-off TrendPairCorr
  0.33CVX Chevron Corp Financial Report 26th of July 2024 PairCorr

Neurobo Stock Highlights

ESG Sustainability
Environmental
Governance
Social
President CEOHyungHeon Kim
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover2.0E-43.0E-4
Fairly Down
Slightly volatile
Total Current Liabilities6.1 MM
Fairly Up
Slightly volatile
Non Current Liabilities Total129.2 K136 K
Notably Down
Very volatile
Total Assets18.4 M22.8 M
Significantly Down
Slightly volatile
Total Current Assets18.1 M22.5 M
Significantly Down
Slightly volatile
Debt Levels
Neurobo Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neurobo Pharmaceuticals' financial leverage. It provides some insight into what part of Neurobo Pharmaceuticals' total assets is financed by creditors.
Liquidity
Neurobo Pharmaceuticals currently holds 203 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Neurobo Pharmaceuticals has a current ratio of 7.91, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neurobo Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Other Non Cash Items

(2.48 Million)
Neurobo Pharmaceuticals (NRBO) is traded on NASDAQ Exchange in USA. It is located in 200 Berkeley Street, Boston, MA, United States, 02116 and employs 8 people. Neurobo Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 35.35 M. Neurobo Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.22 M outstanding shares of which 92.6 K shares are now shorted by private and institutional investors with about 1.2 trading days to cover. Neurobo Pharmaceuticals currently holds about 8.85 M in cash with (10.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Neurobo Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Neurobo Pharmaceuticals is $35.35 Million. Neurobo Pharmaceuticals secures majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 67.85 % of Neurobo Pharmaceuticals outstanding shares that are owned by insiders conveys that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Neurobo Ownership Details

Neurobo Stock Institutional Holders

InstituionRecorded OnShares
Comerica Bank2024-03-31
2.0
Bank Of America Corp2024-03-31
1.0
Hudson Bay Capital Management Lp2024-03-31
0.0
Ubs Group Ag2023-12-31
0.0
Virtu Financial Llc2023-12-31
0.0
Two Sigma Securities, Llc2023-12-31
0.0
Vanguard Group Inc2024-03-31
28 K
Geode Capital Management, Llc2024-03-31
20.7 K
State Street Corporation2024-03-31
15.6 K
Northern Trust Corp2024-03-31
13.5 K
Susquehanna International Group, Llp2024-03-31
12.5 K
View Neurobo Pharmaceuticals Diagnostics

Neurobo Pharmaceuticals Historical Income Statement

At this time, Neurobo Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 25th of July 2024, Other Operating Expenses is likely to grow to about 18.8 M, while Depreciation And Amortization is likely to drop 6,650. View More Fundamentals

Neurobo Stock Against Markets

Neurobo Pharmaceuticals Corporate Management

Additional Information and Resources on Investing in Neurobo Stock

When determining whether Neurobo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurobo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurobo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurobo Pharmaceuticals Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurobo Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.3
Return On Assets
(0.52)
Return On Equity
(1.08)
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.